Analyst firms · Morgan Stanley · GH
Morgan Stanley GH price target and rating history
Guardant Health Inc. (GH) · Health Care
Morgan Stanley rates Guardant Health Inc. (GH) Overweight with a $130 price target, as of its latest action on Dec 2, 2025. It has published 3 rating actions on GH since February 2022, including 0 upgrades and 0 downgrades. Across 11 firms with a GH price target in the last 12 months, the median target is $165. Morgan Stanley's $130 is 21% below that.
- Current rating
- Overweight
- Price target
- $130
- Median target, all firms
- $165
- Actions on GH
- 3
Morgan Stanley price target on GH
Every Morgan Stanley rating on GH
- Dec 2, 2025
- Feb 24, 2022
- Feb 15, 2022
How other firms rate GH
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Roth Capital | Buy | $200 | Oct 23, 2026 |
| UBS | Buy | $225 | Sep 9, 2026 |
| Rothschild & Co Redburn | Buy | $203 | Sep 8, 2026 |
| Bernstein | Outperform | $175 | Jun 26, 2026 |
| RBC Capital Markets | Outperform | $185 | Jun 12, 2026 |
| Goldman Sachs | Buy | $165 | Jun 5, 2026 |
| Wolfe Research | Outperform | $150 | Jun 2, 2026 |
| Evercore ISI | Outperform | $160 | Jun 2, 2026 |
| Canaccord Genuity | Buy | $135 | Feb 20, 2026 |
| Robert W. Baird | Outperform | $120 | Feb 17, 2026 |
| Morgan Stanley | Overweight | $130 | Dec 2, 2025 |
Questions about Morgan Stanley and GH
- What is Morgan Stanley's price target for GH?
- Morgan Stanley's latest stated price target for Guardant Health Inc. (GH) is $130, from its action on Dec 2, 2025.
- What is Morgan Stanley's rating on GH?
- Morgan Stanley rates GH Overweight, a bullish rating, as of Dec 2, 2025.
- When did Morgan Stanley last change its view on GH?
- On Dec 2, 2025, Morgan Stanley resumes coverage at Overweight, price target $130.
- How does Morgan Stanley's GH target compare with other analysts?
- Across 11 firms with a GH price target in the last 12 months, the median target is $165. Morgan Stanley's $130 is 21% below that.
More GH rating histories
All Morgan Stanley ratingsGH news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.